Our study bridges the gap between clinical observations and epigenetic studies of CRC patients with KRAS and BRAF mutations in stage I CRC through a metabolic aging clock, illustrating a spectrum of malignancy with metabolic aging deviations in this stage. This evidence concerns the gene BRAF and colorectal carcinoma.